Mainz Biomed N.V, a leader in molecular genetics diagnostic solutions for early cancer detection, has announced a strategic collaboration with Trusted Health Advisors, a prominent player in supporting the launch and management

YolTech Therapeutics, a leading biotechnology company specializing in in vivo gene editing therapies for rare genetic diseases, has achieved a significant milestone with the approval of the YOLT-201 investigational new drug application by the Center for Drug Evaluation

Vivoryon Therapeutics N.V. recently disclosed the top-line findings from its Phase 2b European VIVIAD trial of varoglutamstat , an oral glutaminyl cyclase inhibitor being explored for early Alzheimer’s disease

Coave Therapeutics, a genetic medicine company focused on developing innovative therapies, is pleased to announce its receipt of a grant from the ALS Association, part of a $2.9 million allocation to six organizations. These grants support the advancement

NeuroBo Pharmaceuticals, Inc. has obtained its first site Institutional Review Board approval from Dr. Alexander Prezioso, Investigator at Clinical Pharmacology of Miami in Hialeah, FL, to initiate the Phase 1 clinical trial

Form Bio and Ginkgo Bioworks have unveiled an innovative collaboration to revolutionize AAV gene therapy design and development. This partnership combines Ginkgo's expertise in cell programming and biosecurity

Incyte has disclosed that the U.S. Food and Drug Administration has accepted the Biologics License Application for axatilimab, an anti-CSF-1R antibody, for Priority Review. This application targets the treatment of chronic graft-versus-host disease

BeiGene, Ltd. declared today that the U.S. Food and Drug Administration has accepted its Biologics License Application for TEVIMBRA® combined with fluoropyrimidine- and platinum-containing

Genmab A/S and AbbVie have jointly announced that the U.S. Food and Drug Administration has given Priority Review status to their supplemental Biologics License Application

XYRA LLC, a private biopharmaceutical company focused on developing innovative therapies for cardiac rhythm disorders, is pleased to announce an agreement with the FDA regarding the next steps for its drug